Вопросы вакцинации против COVID-19 у реципиентов трансплантатов солидных органов

Вопросы вакцинации против COVID-19 у реципиентов трансплантатов солидных органов

Автор: Парабина Е.В., Константинов Д.Ю., Каабак М.М., Раппопорт Н.Н., Пушкин С.Ю., Селютин А.А., Навасардян А.С., Масликова У.В., Александрова В.Э., Яремин Б.И.

Журнал: Вестник медицинского института "РЕАВИЗ": реабилитация, врач и здоровье @vestnik-reaviz

Рубрика: Новая коронавирусная инфекция COVID-19

Статья в выпуске: 4 (52), 2021 года.

Бесплатный доступ

Цель работы - дать основные ответы на вопросы, посвященные вакцинации реципиентов трансплантатов солидных органов на основе последних источников литературы и клинических рекомендаций. Вакцинация реципиентов трансплантатов солидных органов и лиц, находящихся с ними в постоянном контакте, является обязательным, жизненно важным мероприятием, эффективно снижающим риск смерти от COVID-19. Сомнения в меньшей эффективности в условиях иммуносупрессии или потенциальный риск развития нежелательных реакций значительно уступают риску смерти и развития тяжёлых осложнений. До появления более новых данных режим вакцинации должен строго соответствовать инструкции по медицинскому применению препарата. Перед трансплантацией пациент должен быть обследован по скрининговому протоколу, а также консультирован врачом-трансплантологом, осуществляющим его наблюдение. Возможно, что цельновирионные вакцины (КовиВак) имеют преимущество перед прочими при вакцинации реципиентов солидных органов, но клинический опыт в этом вопросе ещё не получен.

Еще

Covid-19, вакцинация, спутник-v, ковивак, реципиенты солидных органов

Короткий адрес: https://sciup.org/143177463

IDR: 143177463   |   DOI: 10.20340/vmi-rvz.2021.4.COVID.2

Список литературы Вопросы вакцинации против COVID-19 у реципиентов трансплантатов солидных органов

  • Boyarsky BJ, Werbel WA, Avery RA, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021.
  • Benotmane I, Gautier-Vargas G, Cognard N, Olagne J, Heibel F, Braun-Parvez L et al. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021.
  • Sattler A SE, Weber U, Potekhin A, Bachmann F, Budde K, Storz E, Proß V, Bergmann Y, Thole L, Tizian C, Hölsken O, Diefenbach A, Schrezenmeier H, Jahrsdörfer B, Zemojtel T, Jechow K, Conrad C, Lukassen S, Stauch D, Lachmann N, Choi M, Halleck F, Kotsch K. MedRxv. https://doi.org/10.1101/2021.04.06.21254963. Accessed 4/19/2021.
  • Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients. Available from: Yi SG, Knight RJ, Graviss EA, Nguyen DT, Ghobrial RM, Gaber AO et al. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration. Transplantation. 2021.
  • Peled Y RE, Lavee J, Sternik L, Segev A, Wieder-Finesod A, Mandelboim M, Indenbaum V, Levy I, Raanani E, Lustig Y, Rahav G. BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response. J Heart Lung Transplant. 2021.
  • Havlin J SM, Dvorackova E et al. Immunogenicity of BNT162b2 mRNA COVID19 Vaccine and SARS-CoV-2 Infection in Lung Transplant Recipients. Journal of Heart and Lung Transplantation. 2021.
  • Narasimhan M ML, Clark AE, Usmani A, Cao J, Raj E, Torres F, Sarode R, Kaza V, Lacelle C, Muthukumar A. Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. medRxiv 2021.
  • Shostak Y SN, Heching M, Rosengarten D, Shtraichman O, Shitenberg D, Amor SM, Yahav D, Zvi HB, Pert-zov B, Kramer MR. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. The Lancet Resp Med. 2021. v. 5 07.13.2021
  • Miele M, Busa R, Russelli G, Sorrentino MC, Di Bella M, Timoneri F et al. Impaired anti-SARS-CoV-2 Humoral and Cellular Immune Response induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients. Am J Transplant. 2021.
  • Cucchiari D, Egri N, Bodro M, Herrera S, Del Risco-Zevallos J, Casals-Urquiza J et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021.
  • Rozen-Zvi B, Yahav D, Agur T, Zingerman B, Ben-Zvi H, Atamna A et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021.
  • Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021.
  • Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M et al. Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021.
  • Itzhaki Ben Zadok O, Shaul AA, Ben-Avraham B, Yaari V, Ben Zvi H, Shostak Y et al. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study. Eur J Heart Fail. 2021CHC Inc. (n.d.).
  • Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021). Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. https://doi.org/10.1038/s41591-021-01377-8
  • Basic-Jukic N, Jelicic I. SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients. Transpl Infect Dis. 2021:e13628.
  • Tsalouchos A, Rossolini GM, Magg L, Mazzoni A, Annunziato F, Dattolo PC. COVID-19 in a kidney transplant recipient after mRNA-based SARS-CoV-2 vaccination. Transpl Infect Dis. 2021:e13649.
  • Tau N, Yahav D, Schneider S, Rozen-Zvi B, Abu Sneineh M, Rahamimov R. Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients. Am J Transplant. 2021.
  • CDC Director Rochelle Walensky Talks Boosters, Masks and Health Equity. Home - Community Health Center Presents Conversations on Health Care. https://www.chcradio.com/episode/Rochelle-Walensky/579.
  • U.S. Department of Health and Human Services. (2021, June 1). NIH clinical trial evaluating mixed COVID-19 vaccine schedules begins. National Institutes of Health. https://www.nih.gov/news-e vents/news-releases/nih-clinical-trial-evaluating-mixed-covid-19-vaccine-schedules-begins
  • Kamar, N., Abravanel, F., Marion, O., Couat, C., Izopet, J., & Del Bello, A. (2021). Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. New England Journal of Medicine. https://doi.org/10.1056/nejmc2108861
  • Werbel, W. A., Boyarsky, B. J., Ou, M. T., Massie, A. B., Tobian, A. A. R., Garonzik-Wang, J. M., & Segev, D. L. (2021). Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Annals of Internal Medicine. https://doi.org/10.7326/l21-0282
  • Joint Statement about Vaccine Efficacy in Organ Transplant Recipients. AST. ISHLT. ASTS. TTS. TID. IPTA. ISVCA. IRT. IXA. ISODT. SPLIT. I PITA. NATCO. UNOS. CST. ESOT. AASLD. ASHI. ITNS. AOPO. PIDS. https://ishlt.org/ishlt/media/documents/ISHLT-AST_SARS-CoV-2-Vaccination_7-15-21.pdf
  • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini Cet al: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020.
  • Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QEet al: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020.
  • Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CBet al: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020.
  • Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova ASet al: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021,397(10275):671-681.
  • Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. Accessed 3/13/2021 [https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3]
  • Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernan MA, Lipsitch M, Reis B, Balicer RD: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021.
  • Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter Aet al: Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646-1657.
  • Pritchard E MP, Stoesser N, Eyre DW, Gethings O, Vihta K, Jones J, House T, VanSteenHouse H, Bell I Bell JI, Newton JN, Farrar J, Diamond A, Rourke E, Studley R, Crook D, Peto T, Walker AS, Pouwels KB, Coro-navirus Infection Survey team: Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK's COVID-19 Infection Survey. medRxiv Posted April 23, 2021.
  • NYT Vaccinations Tracker. Accessed 3/13/21 [https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html]
  • Shimabukuro TT, Cole M, Su JR: Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021.
  • Blumenthal KG, Robinson LB, Camargo CA, Jr., Shenoy ES, Banerji A, Landman AB, Wickner P: Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA. 2021.
  • Chan BT BP, Odutayo A, Pai M: Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine.medRxiv Posted May 8, 2021 2021.
  • Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattor TH, Tjonnfjord GEet al: Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021.
  • Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S: Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021.
  • Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, Zhang B, Licata C, Clark TA, Shimabukuro TT: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine -United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):680-684.
  • Brian J. Boyarsky WAW, Robin K. Avery, Aaron A. R. Tobian, Allan B. Massie, Dorry L. Segev, Jacqueline M. Garonzik-Wang: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021.
  • Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, Katchman E, Halperin T, Turner D, Goykhman Yet al: Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021.
  • Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients.
  • Peled Y RE, Lavee J, Sternik L, Segev A, Wieder-Finesod A, Mandelboim M, Indenbaum V, Levy I, Raanani E, Lustig Y, Rahav G: BNT162b2 vaccination in heart transplant recipients: clinical experience and anti-bodyresponse. J Heart Lung Transplant. 2021.
  • Havlin J SM, Dvorackova E et al. : Immunogenicity of BNT162b2 mRNA COVID19 Vaccine and SARS-CoV-2 Infection in LungTransplant Recipients. Journal of Heart and Lung Transplantation. 2021.
  • Boyarsky BJ, Ou MT, Greenberg RS, Teles AT, Werbel WA, Avery RK, Massie AB, Segev DL, Garonzik-Wang JM: Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021.
  • Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo Het al: Immunogenicity and Safety of the Adjuvanted Recombinant ZosterVaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. Clin Infect Dis. 2020;70(2):181-190.
  • Natori Y, Shiotsuka M, Slomovic J, Hoschler K, Ferreira V, Ashton P, Rotstein C, Lilly L, Schiff J, Singer Let al: A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. Clin Infect Dis. 2018;66(11):1698-1704.
  • Sette A, Crotty S: Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861-880.
  • SARS-CoV-2 Vaccination in Heart and Lung Transplantation, MCS and PHRecommendations from the ISHLT COVID-19 Task Force. May 21, 2021. https://ishlt.org/ishlt/media/documents/COVID19_Vaccine-Recommendations_5-21 -2021.pdf
  • COVID-19 Treatment Guidelines34017.Montagud-Marrahi E, Cofan F, Torregrosa JV, et al. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients. Am J Transplant. 2020;20(10):2958-2959. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32368838.
  • Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32766815.
  • Sharma A, Bhatt NS, St. Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185-e193. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33482113.
  • Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020;130(12):6656-6667. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32897885.
  • Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383(26):2586-2588. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33259154.
  • Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693-704. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32678530.
  • Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021;preprint. Available at: https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1.
  • Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33631065.
  • American Association for the Study of Liver Diseases. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. 2021. Available at: https://www.aasld.org/sites/default/files/2021 -03/AASLD-COVID19-ExpertPanelConsensusStatement-March92021.pdf. Accessed April 12, 2021.
  • Elens L, Langman LJ, Hesselink DA, et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. Ther Drug Monit. 2020;42(3):360-368. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32304488.
  • Special Considerations in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Therapy Candidates, Donors, and Recipients. Section 84. COVID-19 and Special Populations. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed July 19th, 2021.
Еще
Статья научная
SciUp 2024 © 2024 ©